<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734097</url>
  </required_header>
  <id_info>
    <org_study_id>D9612L00116</org_study_id>
    <secondary_id>NEON</secondary_id>
    <nct_id>NCT00734097</nct_id>
  </id_info>
  <brief_title>A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)</brief_title>
  <acronym>NEON</acronym>
  <official_title>An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how patients with gastro-oesophageal reflux disease
      (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still
      experiencing symptoms will benefit from a change in treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment</measure>
    <time_frame>At Baseline and 8 weeks</time_frame>
    <description>Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment</measure>
    <time_frame>At Baseline and 4 weeks</time_frame>
    <description>Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment</measure>
    <time_frame>At Baseline and 8 weeks</time_frame>
    <description>Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment</measure>
    <time_frame>At Baseline and 4 weeks</time_frame>
    <description>Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.</measure>
    <time_frame>At Baseline and 4 weeks.</time_frame>
    <description>Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.</measure>
    <time_frame>At Baseline and 8 weeks.</time_frame>
    <description>Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Epigastric Pain After 4 Weeks of Treatment</measure>
    <time_frame>At Baseline and 4 weeks</time_frame>
    <description>Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Epigastric Pain After 8 Weeks of Treatment</measure>
    <time_frame>At Baseline and 8 weeks</time_frame>
    <description>Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Epigastric Pain After 8 Weeks of Treatment</measure>
    <time_frame>At Baseline and 8 weeks</time_frame>
    <description>Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Epigastric Pain After 4 Weeks of Treatment</measure>
    <time_frame>At Baseline and 4 weeks</time_frame>
    <description>Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Acid Regurgitation After 8 Weeks of Treatment</measure>
    <time_frame>At Baseline and 8 weeks</time_frame>
    <description>Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Acid Regurgitation After 4 Weeks of Treatment</measure>
    <time_frame>At Baseline and 4 weeks</time_frame>
    <description>Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Nexium 40 mgs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg</intervention_name>
    <description>Once a day</description>
    <arm_group_label>Nexium 40 mgs</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Exam</intervention_name>
    <description>every visit</description>
    <arm_group_label>Nexium 40 mgs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>every visit</description>
    <arm_group_label>Nexium 40 mgs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pregnancy test, if applicable</intervention_name>
    <description>as needed</description>
    <arm_group_label>Nexium 40 mgs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persisting symptoms of GORD despite previous treatment with a full dose proton pump
             inhibitor

          -  informed consent

          -  over 18 years of age

        Exclusion Criteria:

          -  Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to
             enrolment in the study

          -  More than 1 other course of PPI treatment in the previous 12 month

          -  previous use of esomeprazole

          -  presence of alarm symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barquisimeto</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Cristobal</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <results_first_submitted>September 25, 2009</results_first_submitted>
  <results_first_submitted_qc>September 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2012</results_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heartburn</keyword>
  <keyword>reflux</keyword>
  <keyword>proton</keyword>
  <keyword>pump</keyword>
  <keyword>inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with persisting symptoms of Gastroesophageal Reflux Disease (GORD) despite previous treatment with a full dose proton pump inhibitor were enrolled across the Argentina (6 sites), Chile (3 sites) Colombia (9 sites) and Venezuela (2 sites).</recruitment_details>
      <pre_assignment_details>All participants received 8-weeks open label esomeprazole treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Esomeprazole 40mg, Daily</title>
          <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="317">20 participants were screening failure.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unconfirmed pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="317">Full analysis performed in 311</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301">16 patients discontinued after randomization</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esomeprazole 40mg, Daily</title>
          <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at study entry</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment</title>
        <description>Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline</description>
        <time_frame>At Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment</title>
          <description>Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline</description>
          <units>Days per week with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.44" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment</title>
        <description>Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.</description>
        <time_frame>At Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment</title>
          <description>Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.</description>
          <units>Days per week with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.08" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment</title>
        <description>Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment</title>
          <description>Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment</title>
        <description>Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment</title>
          <description>Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.</title>
        <description>Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 4 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.</title>
          <description>Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Days per week with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.</title>
        <description>Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 8 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.</title>
          <description>Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Days per week with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.28" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Epigastric Pain After 4 Weeks of Treatment</title>
        <description>Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Epigastric Pain After 4 Weeks of Treatment</title>
          <description>Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Days per week with pain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Epigastric Pain After 8 Weeks of Treatment</title>
        <description>Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).</description>
        <time_frame>At Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Epigastric Pain After 8 Weeks of Treatment</title>
          <description>Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline.
Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).</description>
          <units>Days per week with pain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Epigastric Pain After 8 Weeks of Treatment</title>
        <description>Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Epigastric Pain After 8 Weeks of Treatment</title>
          <description>Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Epigastric Pain After 4 Weeks of Treatment</title>
        <description>Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Epigastric Pain After 4 Weeks of Treatment</title>
          <description>Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Acid Regurgitation After 8 Weeks of Treatment</title>
        <description>Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Acid Regurgitation After 8 Weeks of Treatment</title>
          <description>Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Acid Regurgitation After 4 Weeks of Treatment</title>
        <description>Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
        <time_frame>At Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 40mg, Daily</title>
            <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Severity of Acid Regurgitation After 4 Weeks of Treatment</title>
          <description>Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from &quot;None&quot; to &quot;Severe&quot;.
Four dimensions are defined for the RDQ – heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).</description>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Esomeprazole 40mg, Daily</title>
          <description>Open-label daily esomeprazole 40 mg, daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness / Hypotension / Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

